Design, synthesis, and anticancer evaluation of benzimidazole and benzothiazole derivatives targeting Hsp70 and FoxM1
- 10 September 2025
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 130, 130401
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01GM123508)
- National Institute on Minority Health and Health Disparities (2U54MD017979-01A1)
- Iran National Science Foundation (97006190)
- Isfahan University of Medical Sciences (140162)
This publication has 67 references indexed in Scilit:
- A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cellsMedical Oncology, 2024
- Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatmentsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023
- A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactionsBioorganic Chemistry, 2019
- Benzimidazoles: A biologically active compoundsArabian Journal of Chemistry, 2017
- Carboxylic Acid (Bio)Isosteres in Drug DesignChemMedChem, 2013
- Quantum mechanical polar surface areaJournal of Computer-Aided Molecular Design, 2012
- FOXM1: From cancer initiation to progression and treatmentBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2012
- The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptideJournal of Peptide Science, 2005
- Hsp70 chaperones: Cellular functions and molecular mechanismCellular and Molecular Life Sciences, 2005
- 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—II Biochemical propertiesNeuropharmacology, 1985